成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 287383-59-9 Chemical Structure| 287383-59-9
Chemical Structure| 287383-59-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 287383-59-9

,{[proInfo.pro_purity]}

Scriptaid is an inhibitor of HDAC with greater effect on acetylated H4.

Synonyms: Scriptide; GCK1026

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Scriptaid

CAS No. :287383-59-9
Formula : C18H18N2O4
M.W : 326.35
SMILES Code : O=C(NO)CCCCCN(C(C1=CC=CC2=CC=CC3=C12)=O)C3=O
Synonyms :
Scriptide; GCK1026
MDL No. :MFCD00386477
InChI Key :JTDYUFSDZATMKU-UHFFFAOYSA-N
Pubchem ID :5186

Safety of Scriptaid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Scriptaid

epigenetics

Isoform Comparison

Biological Activity

Target

  • HDAC

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Human BFUe cells 5 μM 14 days Scriptaid increased γ/γ + β mRNA ratio by 3.27-fold in BFUe cultures PMC2808412
Porcine SCNT embryos 500 nM 15 hours Evaluate the effect of combined Scriptaid and DRB treatment on transcriptional activity in SCNT embryos, results showed combined treatment significantly inhibited transcriptional activity. PMC9697165
Porcine fetal fibroblasts (PFF) 500 nM 15 hours Evaluate the effect of Scriptaid on transcriptional activity, results showed Scriptaid alone did not affect transcriptional activity. PMC9697165
Human pulmonary artery endothelial cells (HPAECs) 8 μM 24 hours Induced expression of extracellular superoxide dismutase (EC-SOD) up to 10-fold, whereas expression of the prooxidant gene NADPH oxidase 4 was decreased by more than 95%. We also found that this differential regulation of anti- and prooxidant gene expression resulted in significant attenuation in the cellular levels of reactive oxygen species. PMC5800886
HepG2 cells 10 μM 24 hours Sensitize HepG2 cells to fenretinide-induced apoptosis PMC3077573
Hep3B cells 10 μM 24 hours Enhance fenretinide-induced apoptosis PMC3077573
Huh7 cells 10 μM 24 hours Enhance fenretinide-induced apoptosis PMC3077573
Oligodendrocytes 1 μM 24 hours Scriptaid provides protection to oligodendrocytes treated with microglial conditioned medium PMC4352818
UM-HACC-2A cells 10 μM 24 hours Scriptaid effectively inhibited Snail expression, induced hyperacetylation of histone H3K9, reduced cell migration, and effectively disrupted tumorspheres. PMC10855771
T98G 5-20 μM 24 hours Scriptaid reduced glioma cell viability by increasing JNK activation and induced apoptosis. PMC3823006
LN229 5-20 μM 24 hours Scriptaid reduced glioma cell viability by increasing JNK activation and induced apoptosis. PMC3823006
A375 cells 1 μM 3 hours Evaluate G4 stabilization and DNA damage response of Scriptaid in melanoma cells, results showed Scriptaid significantly stabilized G4s and induced DNA damage PMC11835489
Rat aortic SMC 6 μM 30 minutes Inhibited mitogen-induced SMC proliferation by preventing Rb protein phosphorylation and cell cycle G1→S phase progression PMC3074344
GM979 cells 2 μM 4 days Scriptaid induced γ gene promoter activity by 2.6-fold PMC2808412
Microglia 1 μM 48 hours Scriptaid indirectly protects oligodendrocytes by modulating microglial polarization and reducing inflammatory responses PMC4352818
HEK293 tau-BiFC cells 3 μM 48 hours To evaluate the effect of Scriptaid on tau aggregation, results showed that Scriptaid significantly increased tau-BiFC fluorescence intensity, indicating increased tau aggregation. PMC6747090
CRL1790 cells 128.8 μM (IC50) 48 hours Evaluate cytotoxic activity of Scriptaid in non-tumoral colon epithelial cells, results showed Scriptaid induced cytotoxicity PMC11835489
HCT116 cells 42.8 μM (IC50) 48 hours Evaluate cytotoxic activity of Scriptaid in colorectal cancer cells, results showed Scriptaid induced cytotoxicity PMC11835489
HT29 cells 8.9 μM (IC50) 48 hours Evaluate cytotoxic activity of Scriptaid in colorectal cancer cells, results showed Scriptaid induced cytotoxicity PMC11835489
SW480 cells 9.6 μM (IC50) 48 hours Evaluate cytotoxic activity of Scriptaid in colorectal cancer cells, results showed Scriptaid induced cytotoxicity PMC11835489
U87 cells 3.2 μM 48h or 72h To verify whether Scriptaid could enhance the inhibitory effect of temozolomide on U87 cell proliferation. Results showed that Scriptaid combined with temozolomide significantly inhibited U87 cell proliferation. PMC11790639
Primary microglia 1 μM 6 hours Scriptaid modulated microglia polarization, reduced pro-inflammatory cytokine secretion, and protected oligodendrocytes from hemoglobin-induced injury. PMC8054714
Human breast CAFs (hCAFs) 10 μM 7 days To study the reversal effect of Scriptaid on CAF marker expression. Results showed Scriptaid reduced the expression of SMA, fibronectin, col1, and palladin. PMC5959903
Murine melanoma CAFs (mCAFs) 10 μM 7 days To study the reversal effect of Scriptaid on CAF marker expression. Results showed Scriptaid reduced the expression of SMA, fibronectin, col1, and palladin. PMC5959903

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
C57BL/6 J mice Controlled cortical impact (CCI) model Intraperitoneal injection 1.5 to 5.5 mg/kg Administered at 30 minutes or 12 hours post-injury, continued for 3 days Scriptaid, when administered at 30 minutes or 12 hours post-injury, significantly reduced lesion volume and attenuated motor and cognitive deficits. Additionally, Scriptaid modulated the PTEN and AKT pathways, increasing the number of surviving neurons and the number/length of their processes in the CA3 region of the hippocampus and the pericontusional cortex. PMC3557358
Mice Traumatic brain injury model Intraperitoneal injection 3.5 mg/kg Injected at 2, 26, and 50 hours post-injury Scriptaid protects white matter integrity by modulating microglial polarization and reducing inflammation PMC4352818
C57BL/6 male mice ICH model Intraperitoneal injection 3.5 mg/kg Administered at 2, 26, and 50 hours post-ICH Scriptaid improved neurological functional recovery, reduced white matter injury, and alleviated neuroinflammation by modulating microglia/macrophage polarization after ICH. PMC8054714
C57BL/6J mice Vascular injury model Intraperitoneal injection 3.5 μg/g The day before injury, on the day of the injury, and every other day thereafter for 28 days Reduced neointima formation and cyclin D1 expression following vascular injury PMC3074344
Mice B16F10 melanoma model Intraperitoneal injection 5.5 mg/kg 3 times per week until the end of the experiment To study the effect of Scriptaid on tumor growth and CAF abundance. Results showed Scriptaid inhibited tumor growth by approximately twofold and significantly reduced the number of SMA+/Col1+ CAFs. PMC5959903
Pigs SCNT embryo transfer model In vitro culture followed by transfer 500 nM Scriptaid + 100 μM DRB Single treatment, lasting 15 hours Evaluate the effect of combined Scriptaid and DRB treatment on SCNT embryo development, results showed combined treatment promoted normal fetal development and production of healthy cloned piglets. PMC9697165

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.32mL

3.06mL

1.53mL

30.64mL

6.13mL

3.06mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories